Contact the Editorial Desk

Editorial correspondence

Smart Choice Peptides welcomes correspondence about the research record itself: a citation quoted inaccurately, a newly published trial result, a regulatory status change, or a peer-reviewed study on AOD-9604, tesamorelin, or tirzepatide that should be added to the references page. Corrections that improve the accuracy or currency of this digest are the most useful messages this desk receives.

The most actionable submissions specify the page in question, the exact passage being challenged, and a supporting reference — a DOI or PubMed identifier wherever possible — so a proposed change can be verified against its source before anything is edited.

Editorial mailbox: editors@smartchoicepeptides.com

What this desk cannot do

So that no message goes unanswered for the wrong reason: Smart Choice Peptides is a literature digest, not a clinical service or a vendor, and it cannot advise on or recommend human use of any compound discussed here, suggest a dose or schedule for any individual, evaluate whether a cited trial's finding applies to someone's specific situation, or sell, source, or help locate any compound from any supplier. Tesamorelin and tirzepatide are prescription medicines available only through licensed providers; AOD-9604 is not an approved medicine anywhere. Readers seeking medical guidance should consult a licensed clinician in their own jurisdiction. Responses to editorial correspondence are not guaranteed, and this mailbox is monitored intermittently.